Dravet Syndrome Treatment Market size is poised to reach USD 1 Billion by the end of 2036, growing at a CAGR of 11% during the forecast period, i.e., 2024 – 2036. In the year 2023, the industry size of dravet syndrome treatment was USD 0.37 Billion. The reason behind the growth is impelled by the increasing child population. Moreover, Dravet syndrome is an uncommon kind of epilepsy that starts in infancy or early childhood and can lead to frequent, protracted seizures, which may require treatment including medication or other therapies to decrease the severity and amount of seizures.According to estimates, the number of children worldwide is projected to be over 1 billion in 2100.
The growing research & development are believed to fuel the dravet syndrome treatment market. For instance, in 2020 STK-001 an anti-sense oligonucleotide was administered, to the first patient with Dravet syndrome as part of a clinical trial to increase the expression of SCN1A in the brain.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~11% |
|
Base Year Market Size (2023) |
~ USD 0.37 Billion |
|
Forecast Year Market Size (2036) |
~ USD 1 Billion |
|
Regional Scope |
|
Product (SGDs, TGDs, FGDs)
The SGDs segment is estimated to account for 45% share of the dravet syndrome treatment market in the coming years. The only SGDs that are currently available for the treatment of DS are stiripentol and topiramate out of which the only medication that has been proven to adequately treat Dravet-related seizures is stiripentol which is available in the form of hard capsules or a powder for oral suspension. Besides this, it can be used as an orphan medication in the supplementary management of childhood epilepsy syndrome.
End-User (Pharmaceutical Companies, Hospital Pharmacies, Diagnostic Laboratories, Academic and Research Institutes)
Dravet syndrome treatment market from the hospital pharmacies segment is set to garner a notable share shortly. Drugs, such as valproate, clobazam, stiripentol, cannabidiol, or fenfluramine, are used to treat patients with Dravet syndrome which are provided by hospital pharmacies as it has the required skills for pricing, dispensing, and the availability of skilled hospital pharmacists to manage these medications.
Treatment Type (Seizure Medications, Ketogenic Diet, Vagus Nerve Stimulation)
The seizure medications segment in the dravet syndrome treatment market is set to garner a significant share during the forecast timeframe. Seizure medications work to halt or prevent seizures by functioning in a variety of ways. For instance, more than 60% of epilepsy sufferers can control their seizures with medication. Moreover, anti-seizure drugs function by lessening the aberrant electrical activity in the brain and help in managing the type of pain brought on by damaged nerves.
Diagnosis Type (Magnetic Resonance Imaging, Electroencephalography, SCN1 A Testing)
The magnetic resonance imaging segment in the dravet syndrome treatment market is set to garner a significant share by the year 2036. Dravet syndrome (DS) and other neurological conditions may be distinguished using (MRI) since it creates extremely accurate images of a child's brain using a magnetic field and radio waves.
Our in-depth analysis of the global market includes the following segments:
|
Seizures Type |
|
|
Diagnosis Type |
|
|
End-User |
|
|
Treatment Type |
|
|
Product |
|
North American Market Forecast
Dravet syndrome treatment market in North America is predicted to account for the largest share of 39% by 2036 impelled by the rising spending in healthcare. This has led to an increase in research & development of more efficient and effective treatments for Dravet syndrome in the region, which would also improve access to the treatment of the disease in the region. According to estimates, in 2021, the United States spent over 2% more on health care, amounting to roughly USD 4 trillion.
European Market Statistics
The Europe dravet syndrome Treatment market is estimated to be the second largest, during the forecast timeframe led by growing development of new drugs. For instance, Europe serves as the world's center for medication development, as over 72 novel opioids have been discovered on the European drug market between 2009 and 2022. This has led to an expansion in treatment options for Dravet syndrome in the region.
Author Credits: Radhika Gupta, Shivam Bhutani
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?